Carlyle in talks to buy Baxter’s Vantive business for over $4B, WSJ reports

Private-equity firm Carlyle (CG) is in exclusive talks to acquire medical device maker Baxter’s kidney care spinoff Vantive for more $4B, including debt, according to The Wall Street Journal’s Laura Cooper. The two parties entered exclusive negotiations in late June and a deal could be announced in the coming weeks, people familiar with the situation told The Journal, but added that it is still possible talks could fall apart or another suitor could prevail. The separation of Vantive, which had about $4.5B in revenue last year, was expected to take place in the second half of this year, the report noted.